Alume Biosciences Appoints Kaveri Parker as Chief Business Officer

, /PRNewswire/ -- Alume Biosciences, a late-clinical stage biotechnology company developing nerve illuminating technology to potentially make surgery safer, today announced the appointment of Kaveri Parker, Ph.D. as Chief Business Officer. Dr. Parker is a forward-thinking biopharma leader and joins Alume Biosciences with deep experience in strategy and operations leadership roles.

"We are pleased to welcome Kaveri to our growing team and are confident her vision will help us advance the field of fluorescent-guided surgery for the benefit of patients and surgeons," said Quyen Nguyen, M.D., Ph.D., Alume Biosciences Chief Executive Officer. "Kaveri brings a track-record of success across licensing agreements, partnership development, financing and more. Her deep expertise and insights providing strategic guidance in biopharma will be critical as we approach potential FDA approval for our lead candidate, bevonescein, and as we grow as a company."

"I am thrilled to join Alume at this key stage in the Company's development as we are poised to advance an important product candidate at the forefront of fluorescent-guided surgery," said Dr. Parker. "Surgical safety is a key area with room for improvement across the industry and Alume's approach has the potential for tangible impact in patients' lives. I am eager to work with the full team to identify key pathways for growth and commercialization opportunities."

Prior to joining Alume Biosciences, Dr. Parker was the Chief Business Officer of Synedgen, Inc. where she oversaw commercial, strategic and business development activities for the Company's drug and medical device assets. While at Synedgen, Dr. Parker secured both dilutive and non-dilutive funding for complex and high-risk programs and was the co-architect of the Company's $110M contract with the Biomedical Advanced Research and Development Authority (BARDA). She also secured high-value partnerships with public and private stakeholders. She additionally serves as the strategic and commercialization lead for a national pandemic preparedness team at the Mayo Clinic. She has ongoing Strategy and Transaction Advisory roles with multiple private companies. She was previously the President and CEO of ID Genomics, a company focused on antibiotic susceptibility testing. Dr. Parker has a Ph.D. from Washington University School of Medicine in Saint Louis.

About Alume Biosciences
Alume Biosciences is on a mission to make our proprietary nerve illumination technology available for surgeons so that patients everywhere can benefit. Alume was born out of a collaboration between head and neck surgeon Dr. Quyen Nguyen and Nobel Laureate Dr. Roger Tsien working to advance nerve illuminating technology to protect and preserve nerve function in surgery. Learn more at alumebiosciences.com and LinkedIn.

Media Contact
Janine Bogris
[email protected]
201-245-6838

SOURCE Alume Biosciences